201 related articles for article (PubMed ID: 8831043)
1. Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria.
Eliopoulos GM; Wennersten CB; Moellering RC
Diagn Microbiol Infect Dis; 1996 May; 25(1):35-41. PubMed ID: 8831043
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of levofloxacin against gram-positive bacteria.
Montanari MP; Mingoia M; Marchetti F; Varaldo PE
Chemotherapy; 1999; 45(6):411-7. PubMed ID: 10567771
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.
Cafiso V; Messina C; Santagati M; Campanile F; Bonfiglio G; Stefani S
Drugs Exp Clin Res; 2001; 27(3):107-11. PubMed ID: 11447768
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the in vitro activity of levofloxacin and other antimicrobial agents against vancomycin-susceptible and vancomycin-resistant Enterococcus species.
Hayden MK; Matushek MG; Trenholme GM
Diagn Microbiol Infect Dis; 1995 Aug; 22(4):349-52. PubMed ID: 8582142
[TBL] [Abstract][Full Text] [Related]
5. Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.
Dholakia N; Rolston KV; Ho DH; LeBlanc B; Bodey GP
Antimicrob Agents Chemother; 1994 Apr; 38(4):848-52. PubMed ID: 8031057
[TBL] [Abstract][Full Text] [Related]
6. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.
Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 1997 Aug; 41(8):1662-7. PubMed ID: 9257737
[TBL] [Abstract][Full Text] [Related]
7. Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.
Nicas TI; Mullen DL; Flokowitsch JE; Preston DA; Snyder NJ; Stratford RE; Cooper RD
Antimicrob Agents Chemother; 1995 Nov; 39(11):2585-7. PubMed ID: 8585753
[TBL] [Abstract][Full Text] [Related]
8. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.
Giamarellos-Bourboulis EJ; Sambatakou H; Grecka P; Giamarellou H
Eur J Clin Microbiol Infect Dis; 1998 Sep; 17(9):657-61. PubMed ID: 9832270
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of sparfloxacin, ciprofloxacin, ofloxacin, and other antibiotics against bloodstream isolates of gram-positive cocci.
Rotstein C; Amsterdam D; Beam TR; Mandell LA; Gorzynski EA
Diagn Microbiol Infect Dis; 1993 Jul; 17(1):85-91. PubMed ID: 8395375
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the synergistic interactions of levofloxacin and ampicillin against Enterococcus faecium by the checkerboard agar dilution and time-kill methods.
Smith CE; Foleno BE; Barrett JF; Frosco MB
Diagn Microbiol Infect Dis; 1997 Mar; 27(3):85-92. PubMed ID: 9147009
[TBL] [Abstract][Full Text] [Related]
12. European Glycopeptide Susceptibility Survey of gram-positive bacteria for 1995. European Glycopeptide Resistance Survey Study Group.
Felmingham D; Brown DF; Soussy CJ
Diagn Microbiol Infect Dis; 1998 Aug; 31(4):563-71. PubMed ID: 9764397
[TBL] [Abstract][Full Text] [Related]
13. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
[TBL] [Abstract][Full Text] [Related]
14. The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin-susceptible and vancomycin-resistant enterococci.
Itokazu GS; Nathan C; Hariharan R; Kostman JR; Kabins SA; Weinstein RA
Chemotherapy; 1996; 42(4):235-9. PubMed ID: 8804789
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic and molecular antibiotic resistance profile of Enterococcus faecalis and Enterococcus faecium isolated from different traditional fermented foods.
Sánchez Valenzuela A; Lavilla Lerma L; Benomar N; Gálvez A; Pérez Pulido R; Abriouel H
Foodborne Pathog Dis; 2013 Feb; 10(2):143-9. PubMed ID: 23259502
[TBL] [Abstract][Full Text] [Related]
16. In-vitro activity of ofloxacin, levofloxacin and D-ofloxacin against staphylococci.
von Eiff C; Peters G
J Antimicrob Chemother; 1996 Aug; 38(2):259-63. PubMed ID: 8877540
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of sparfloxacin (AT-4140 and CI-978), a new quinolone antimicrobial agent, against Haemophilus and gram-positive cocci.
Rudrik JT; Ferrigno SR; Gee SL
Diagn Microbiol Infect Dis; 1991; 14(4):355-60. PubMed ID: 1889186
[TBL] [Abstract][Full Text] [Related]
18. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
[TBL] [Abstract][Full Text] [Related]
19. In vitro effect of levofloxacin and vancomycin combination against high level aminoglycoside-resistant enterococci.
Erdem I; Cicek-Senturk G; Yucesoy-Dede B; Yuksel-Kocdogan F; Yuksel S; Karagul E
Int J Antimicrob Agents; 2004 Jan; 23(1):92-4. PubMed ID: 14732321
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species.
Zhanel GG; Karlowsky JA; Hoban DJ
Diagn Microbiol Infect Dis; 1998 Jun; 31(2):343-7. PubMed ID: 9635908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
